Volume : 12, Issue : 11, November – 2025
Title:
FORMULATION AND EVALUATION OF PROLIPOSOME POWDER FOR IMPROVED ORAL BIOAVAILABILITY OF A POORLY SOLUBLE DRUG
Authors :
Anand Shivkumar Khode*, Vedangi Vijay Raut, Sonali Arun Kantale, Rupeshri Ravindra Netkar, Gaurav Gautam Manwar
Abstract :
The present study focuses on the formulation and evaluation of a proliposome powder as a novel lipid-based drug delivery system aimed at improving the oral performance of a poorly soluble glucocorticoid. Although this class of drugs demonstrates potent anti-inflammatory and immunosuppressive effects and is widely used for the management of autoimmune and inflammatory disorders such as rheumatoid arthritis, asthma, and inflammatory bowel disease, its therapeutic efficacy is often limited by low aqueous solubility, poor bioavailability, and systemic adverse effects.
In this research, proliposome powders were prepared using the solvent evaporation method, employing various lipids and surfactants to optimize encapsulation efficiency, stability, and drug release characteristics. Six formulations were developed, among which Batch 4 exhibited superior performance and was selected as the optimized formulation. The developed proliposome powder was evaluated for key physicochemical properties such as particle size, morphology, drug loading, and entrapment efficiency, which ranged from 84.64 ± 0.5% to 91.01 ± 0.6%. In vitro dissolution studies revealed a controlled and enhanced drug release profile, ranging between 83.48% and 93.60%, under simulated physiological conditions.
The outcomes of this investigation suggest that the proliposome-based system effectively enhances solubility, bioavailability, and overall therapeutic efficacy. Hence, the developed formulation may serve as a promising approach to improve patient compliance and treatment outcomes in chronic inflammatory and autoimmune diseases requiring glucocorticoid therapy.
Keywords: Proliposome, lipid-based delivery, glucocorticoid therapy, oral bioavailability, inflammatory disorders
Cite This Article:
Please cite this article in press Anand Shivkumar Khode et al., Formulation And Evaluation Of Proliposome Powder For Improved Oral Bioavailability Of A Poorly Soluble Drug, Indo Am. J. P. Sci, 2025; 12(11).
REFERENCES:
1. Patel J, Patel A, Raval M, Sheth N. Formulation and development of proliposome for oral delivery of poorly water-soluble drug: A review. Int J Drug Deliv. 2012;4(1):26-37.
2. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-60.
3. Jain S, Kumar D, Swarnakar NK, Thanki K. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials. 2012;33(26):6758-68.
4. Chauhan N, Mehta P, Soni TG, Patel CN. Development of proliposomes for oral delivery of poorly water-soluble drug glipizide. J Pharm Bioallied Sci. 2012;4(2):S65-6.
5. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102.
6. Sharma D, Sharma RK, Gupta R, Sharma A. Liposomes: emerging trends in targeted drug delivery. J Drug Deliv Ther. 2012;2(2):54-9.
7. Pardeshi CV, Belgamwar VS. Controlled synthesis of proliposomes as a novel vesicular carrier for oral drug delivery. J Nanostruct Chem. 2016;6(3):207-19.
8. Ruckmani K, Sankar V. Formulation and optimization of Zidovudine proliposomes using response surface methodology. Int J Pharm. 2010;385(1-2):131-41.
9. Payne NI, Timmins P, Ambrose CV, Ward MD, Ridgway F. Proliposomes: A novel solution to an old problem. J Pharm Sci. 1986;75(4):325-9.
10. Sharma A, Sharma US. Liposomes in drug delivery: Progress and limitations. Int J Pharm. 1997;154(2):123-40.
11. Jagwani S, Verma S, Pandey P, Nema RK. Proliposomes: A surrogate carrier for improved solubility and bioavailability of poorly water-soluble drugs. J Drug Deliv Ther. 2013;3(4):56-65.
12. Manosroi A, Khanrin P, Lohcharoenkal W, Werner RG, Manosroi J. Entrapment enhancement of prednisolone and prednisolone acetate in proliposome powders by using freeze drying. Drug Dev Ind Pharm. 2012;38(1):68-75.
13. Jain S, Tiwary AK, Sapra B, Jain NK. Formulation and evaluation of ethosomes for transdermal delivery of lamivudine. AAPS PharmSciTech. 2007;8(4):E111.
14. Kulkarni SB, Betageri GV, Singh M. Factors influencing the entrapment efficiency of proliposomes. AAPS PharmSciTech. 2000;1(1):1-8.
15. Elhissi A, Ahmed W, Hassan IU, Dhanak V, Taylor KMG. Proliposome powders for the generation of inhalable liposomes by nebulization. Int J Pharm. 2012;436(1-2):519-26.
16. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231-48.
17. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2(3):289-300.
18. Anindya Bagchi, P. Mukherjee, Indeerjet kaur, Ramandeep Singh, Alok Semwal. Development and validation of UV spectrophotometric method forestimation of Deflazacort in bulk drug and Pharmaceutical formulation. Int. J. Drug Dev. & Res., July-September 2012, 4 (3): 369-373.
19. Vemuri S, Rhodes CT. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv. 1995;70(2):95–111.
20. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm. 1997;154(2):123–140.
21. Bendas ER, Tadros MI. Enhanced transdermal delivery of salbutamol sulfate using liposomes. Drug Dev Ind Pharm. 2007;33(1):19–26.
22. Jaafar-Maalej C, Elaissari A, Fessi H. Lipid-based carriers: manufacturing and applications for pulmonary route. Expert Opin Drug Deliv. 2012;9(9):1111–1127.
23. Perrett S, Golding M, Williams WP. A simple method for the preparation of liposomes for pharmaceutical applications: characterization of the liposomes. J Pharm Pharmacol. 1991;43(3):154–161.
24. Elhissi AM, Karnam KK, Danesh-Azari MR, Gill HS, Taylor KM. Formulations generated from proliposomes for delivery via pressurized metered dose inhalers. Eur J Pharm Sci. 2006;28(5):413–424.
25. Elhissi AM, Faizi M, Naji WF, Gill HS, Taylor KM. Physical stability and aerosol properties of liposomes delivered via nebulizer. J Liposome Res. 2007;17(2):113–125.
26. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83(5):761–769.
27. Mozafari MR. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett. 2005;10(4):711–719.
28. Lasic DD. Liposomes: from physics to applications. Amsterdam: Elsevier; 1993.
29. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102.
30. Shehata T, Ibrahim A, El Shamy A, El-Kamel AH. Development and stability of proliposomes for improved oral delivery of poorly soluble drugs. Drug Dev Ind Pharm. 2016;42(12):1977–1989.
31. Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Indian J Pharm Sci. 2008;70(3):269–277.
32. Sutradhar KB, Amin ML. Nanotechnology in cancer drug delivery and selective targeting. ISRN Nanotechnol. 2014;2014:939378.
33. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13(1):238–252.
34. Yadav AV, Shete AS, Dabke AP, Kulkarni PV, Sakhare SS. Co-crystals: a novel approach to modify physicochemical properties of active pharmaceutical ingredients. Indian J Pharm Sci. 2009;71(4):359–370.
35. Mehta RM, Bhardwaj SP, Pathak K. Proliposomes as dry powder delivery systems for oral delivery of amphotericin B. Drug Dev Ind Pharm. 2008;34(8):762–769.
36. Chougule M, Padhi B, Misra A. Development of dry powder inhalers containing liposomes of budesonide for pulmonary delivery. AAPS PharmSciTech. 2008;9(4):1034–1042.
37. Ghanbarzadeh S, Arami S. Enhanced transdermal delivery of diclofenac sodium via conventional liposomes, ethosomes, and transfersomes. Biomed Res Int. 2013;2013:616810.
38. Nekkanti V, Venkatesan N, Betageri GV. Proliposomes for oral delivery: progress and challenges. Curr Pharm Biotechnol. 2015;16(4):303–312.
39. Karthik Y., Raju J., Ashok V., Sharath S., Suresh B.,Prabhakar K., Prabhakar Reddy V. Bioavailability enhancement of zaleplon via proliposomes: Role of surface charge. European Journal of Pharmaceutics and Biopharmaceutics 2012, (80) 347–357.
40. Rasve, V. R., & Chakraborty, A. (2022). A comprehensive review on self-microemulsifying drug delivery systems (SMEDDS). International Journal of Pharmacy and Pharmaceutical Research, 26(1), 206–224.
41. Raju J., Sruthi S.,Suresh B.,Prabhakar R. Veera R. Enhanced Bioavailability of Exemestane Via Proliposomes based Transdermal Delivery. Journal of Pharmaceutical Sciences 2011, 100 (8) 3208–3222.
42. Barthel L.,Woodley J., Kenworthy S.,Houin G., An improved everted gut sac as a simple and accurate technique to measure paracellular transport across the small intestine. Journal of Pharmacology 2008, 247, 235-241.
43. Mallesh K., Srinivas C., Nagasree K., Prakash V. D. Formulation and Evaluation of Prednisolone Proliposomal Gel for Effective Topical Pharmacotherapy. International Journal of Pharmaceutical Sciences and Drug Research 2012, 4(1) 35-43.